PMID- 26119690
OWN - NLM
STAT- MEDLINE
DCOM- 20150930
LR  - 20220318
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 464
IP  - 1
DP  - 2015 Aug 14
TI  - Intravenous immunoglobulin enhances the killing activity and autophagy of 
      neutrophils isolated from immunocompromised patients against multidrug-resistant 
      bacteria.
PG  - 94-9
LID - S0006-291X(15)30059-0 [pii]
LID - 10.1016/j.bbrc.2015.06.004 [doi]
AB  - Intravenous immunoglobulin (IVIG) is periodically administered to 
      immunocompromised patients together with antimicrobial agents. The evidence that 
      supports the effectiveness of IVIG is mostly based on data from randomized 
      clinical trials; the underlying mechanisms are poorly understood. A recent study 
      revealed that killing of multidrug-resistant bacteria and drug-sensitive strains 
      by neutrophils isolated from healthy donors is enhanced by an IVIG preparation. 
      However, the effectiveness of IVIG in immunocompromised patients remains unclear. 
      The present study found that IVIG increased both killing activity and O2(-) 
      release by neutrophils isolated from six patients receiving immune-suppressive 
      drugs after hematopoietic stem cell transplantation (HSCT); these neutrophils 
      killed both multidrug-resistant extended-spectrum beta-lactamase-producing 
      Escherichia coli (E. coli) and multidrug-resistant Pseudomonas aeruginosa 
      (P. aeruginosa). Moreover, IVIG increased the autophagy of the neutrophils, which 
      is known to play an important role in innate immunity. These results suggest that 
      IVIG promotes both the killing activity and autophagy of neutrophils isolated 
      from immunocompromised patients against multidrug-resistant bacteria.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Matsuo, Hidemasa
AU  - Matsuo H
AD  - Department of Human Health Sciences, Graduate School of Medicine, Kyoto 
      University, Kyoto 606-8507, Japan; Department of Clinical Laboratory, Kyoto 
      University Hospital, Kyoto 606-8507, Japan.
FAU - Itoh, Hiroshi
AU  - Itoh H
AD  - Department of Human Health Sciences, Graduate School of Medicine, Kyoto 
      University, Kyoto 606-8507, Japan.
FAU - Kitamura, Naoko
AU  - Kitamura N
AD  - Department of Human Health Sciences, Graduate School of Medicine, Kyoto 
      University, Kyoto 606-8507, Japan.
FAU - Kamikubo, Yasuhiko
AU  - Kamikubo Y
AD  - Department of Human Health Sciences, Graduate School of Medicine, Kyoto 
      University, Kyoto 606-8507, Japan.
FAU - Higuchi, Takeshi
AU  - Higuchi T
AD  - Department of Clinical Laboratory, Kyoto University Hospital, Kyoto 606-8507, 
      Japan.
FAU - Shiga, Shuichi
AU  - Shiga S
AD  - Department of Clinical Laboratory, Kyoto University Hospital, Kyoto 606-8507, 
      Japan.
FAU - Ichiyama, Satoshi
AU  - Ichiyama S
AD  - Department of Infection Control and Prevention, Kyoto University Hospital, Kyoto 
      606-8507, Japan.
FAU - Kondo, Tadakazu
AU  - Kondo T
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto 
      University, Kyoto 606-8507, Japan.
FAU - Takaori-Kondo, Akifumi
AU  - Takaori-Kondo A
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto 
      University, Kyoto 606-8507, Japan.
FAU - Adachi, Souichi
AU  - Adachi S
AD  - Department of Human Health Sciences, Graduate School of Medicine, Kyoto 
      University, Kyoto 606-8507, Japan. Electronic address: 
      adachiso@kuhp.kyoto-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150625
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunosuppressive Agents)
RN  - 11062-77-4 (Superoxides)
RN  - EC 3.5.2.6 (beta-Lactamases)
SB  - IM
MH  - Adult
MH  - Anti-Bacterial Agents/pharmacology
MH  - Autophagy/drug effects/immunology
MH  - Coculture Techniques
MH  - Drug Resistance, Multiple, Bacterial
MH  - Escherichia coli/drug effects/growth & development/immunology
MH  - Female
MH  - Hematologic Neoplasms/*immunology/pathology/therapy
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - *Immunocompromised Host
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Male
MH  - Microbial Sensitivity Tests
MH  - Middle Aged
MH  - Neutrophils/cytology/drug effects/*immunology
MH  - Primary Cell Culture
MH  - Pseudomonas aeruginosa/drug effects/growth & development/immunology
MH  - Superoxides/*agonists/metabolism
MH  - beta-Lactamases/biosynthesis
OTO - NOTNLM
OT  - Autophagy
OT  - Immunocompromised host
OT  - Intravenous immunoglobulin
OT  - Multidrug-resistant bacteria
OT  - Neutrophil
EDAT- 2015/06/30 06:00
MHDA- 2015/10/01 06:00
CRDT- 2015/06/30 06:00
PHST- 2015/05/11 00:00 [received]
PHST- 2015/06/02 00:00 [accepted]
PHST- 2015/06/30 06:00 [entrez]
PHST- 2015/06/30 06:00 [pubmed]
PHST- 2015/10/01 06:00 [medline]
AID - S0006-291X(15)30059-0 [pii]
AID - 10.1016/j.bbrc.2015.06.004 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2015 Aug 14;464(1):94-9. doi: 
      10.1016/j.bbrc.2015.06.004. Epub 2015 Jun 25.